Serum α-fetoprotein (AFP) is sometimes high in patients with primary gastric carcinoma, and there is no comprehensive study on the clinicopathologic characteristics and prognostic factors of AFP-producing gastric carcinoma (AGC). To clarify the variables associated with the survival after gastrectomy for AGC, we reviewed the data of patients with AGC and examined the independent prognostic factors. We studied 270 cases of AGC reported in the Japanese literature from June 1982 to March 2001, together with 1 patient of our own experience. The clinicopathologic findings, including serum AFP level, operative curability, and stage of the disease were examined, and factors associated with survival were determined by multivariate analysis. There were 15 stage I tumors (6%), 50 stage II tumors (19%), 51 stage III tumors (20%), and 145 stage IV tumors (55%). The tumors were characterized by frequent serosal invasion (75%), lymph node metastasis (83%), liver metastasis (33%), stage III or IV disease (75%), and noncurative operation (48%). The survival was influenced by the serum AFP level, tumor size, serosal invasion, lymph node metastasis, and liver metastasis, but the independent prognostic factors were operative curability (curative vs. noncurative) and stage of the disease (I, II vs. III, IV). Although the 5-year survival rate and median survival period in all patients were 22% and 14 months, respectively, those in patients with curative gastrectomy were 42% and 29 months, respectively. The results indicate that operative curability and stage of the disease are factors associated with the survival of patients with AGC. Although tumors are often advanced and complicated with liver metastases, long-term survival can be achieved when patients with stage I or II tumor undergo curative gastrectomy.

1.
Nishimura H, Okamoto Y, Takahashi M, Fujita T: Occurrence of alpha-fetoprotein, Regan isoenzyme, and variant alkaline phosphatase in the serum of a patient with gastric cancer. Gastroenterology 1976;71:497–499.
2.
Bourreille J, Metayer P, Sauger F, Matray F, Fondimare A: Existence d’alpha foetoproteine au cours d’un cancer secondaire du foie d’origine gastrique. Presse Méd 1970;78:1277–1278.
3.
Kudo M, Takamine Y, Nakamura K, Shirane H, Uchida H, Kasakura S, Kajiwara T, Ibuki Y, Hirasa M, Tomita S, Todo A: Des-gamma-carboxy prothrombin (PIVKA-II) and alpha-fetoprotein-producing IIc-type early gastric cancer. Am J Gastroenterol 1992;87:1859–1862.
4.
Kubota O, Suzuki T, Takahashi T, Kosukegawa M, Yamashita K, Mori S, Mochizuki K, Futami H, Takai T, Shamoto M: A case of AFP-producing early gastric carcinoma with rapid growth liver metastasis. Hepatogastroenterology 2001;48:1206–1208.
5.
Kono K, Amemiya H, Sekikawa T, Iizuka H, Takahashi A, Fujii H, Matsumoto Y: Clinicopathologic features of gastric cancers producing alpha-fetoprotein. Dig Surg 2002;19:359–365.
6.
Chang YC, Nagasue N, Kohno H, Tanimura H, Uchida M, Yamanoi A, Kimoto T, Nakamura T: Clinicopathologic features and long-term results of alpha-fetoprotein-producing gastric cancer. Am J Gastroenterol 1990;85:1480–1485.
7.
Chang YC, Nagasue N, Abe S, Kohno H, Kumar DD, Nakamura T: Alpha fetoprotein producing early gastric cancer with liver metastasis: Report of three cases. Gut 1991;32:542–545.
8.
Tsurumachi T, Yamamoto H, Watanae K, Honda I, Watanabe S, Yamada S, Jingu K, Satomi D, Fujita M: Resection of liver metastasis from alpha-fetoprotein-producing early gastric cancer: Report of a case. Surg Today 1997;27:563–566.
9.
Sato Y, Nishimaki T, Date K, Shirai Y, Kurosaki I, Saito Y, Watanabe T, Hatakeyama K: Successful resection of metachronous liver metastasis from alpha-fetoprotein-producing gastric cancer: Report of a case. Surg Today 1999;29:1075–1078.
10.
Ooi A, Nakanishi I, Sakamoto N, Tsukada Y, Takahashi Y, Minamoto T, Mai M: Alpha-fetoprotein (AFP)-producing gastric carcinoma: Is it hepatoid differentiation? Cancer 1990;65:1741–1747.
11.
Matsunou H, Konishi F, Jalal REA, Yamamichi N, Mukawa A: Alpha-fetoprotein-producing gastric carcinoma with enteroblastic differentiation. Cancer 1994;73:534–540.
12.
Shimanuki K, Miyata M, Kiyozaki H, Satake M, Shinohara K, Suzuki W, Kai T, Yamada S: A case of alpha-fetoprotein-producing gastric cancer with pronounced liver metastasis after open heart surgery (in Japanese with English abstract). Jpn J Gastroenterol Surg 1993;26:1057–1061.
13.
Miyairi K, Imai S, Shibuya T, Ohba H, Uchiyama K, Suzuki S, Nanbu K, Yamamoto H, Suda H, Shouji T: Two cases of AFP-producing gastric cancer confirmed immunohistologically (in Japanese with English abstract). J Jpn Soc Clin Surg 1993;54:2285–2291.
14.
Fujiya T, Ohgoshi T, Mikuni J, Kakugawa Y, Kamiyama Y, Sugawara T, Ouchi K, Sato I, Tateno H: A case of early gastric cancer producing alpha-fetoprotein (in Japanese with English abstract). Jpn J Gastroenterol Surg 1996;29:732–736.
15.
Sugawara Y, Konishi T, Hiraishi M, Sato A, Natomi H, Aoki T, Makuuchi M: Hepatoid adenocarcinoma of the stomach: A case report. Hepatogastroenterology 1996;43:995–999.
16.
Inagawa S, Shimazaki J, Hori M, Yoshimi F, Adachi S, Kawamoto T, Fukao K, Itabashi M: Hepatoid adenocarcinoma of the stomach (case report). Gastric Cancer 2001;4:43–52.
17.
Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma; 2nd English edition. Gastric Cancer 1998;1:10–24.
18.
Adachi Y, Yasuda K, Inomata M, Sato K, Shiraishi N, Kitano S: Pathology and prognosis of gastric carcinoma: Well versus poorly differentiated type. Cancer 2000;89:1418–1424.
19.
Alpert E, Pinn VW, Isselbacher KJ: Alpha-fetoprotein in a patient with gastric carcinoma metastatic to the liver. N Engl J Med 1971;285:1058–1059.
20.
Kozower M, Fawaz KA, Miller HM, Kaplan MM: Positive alpha-fetoglobulin in a case of gastric carcinoma. N Engl J Med 1971;285:1059–1060.
21.
Mehlman DJ, Bulkley BH, Wiernik PH: Serum alpha1-fetoglobulin with gastric and prostatic carcinomas. N Engl J Med 1971;285:1060–1061.
22.
Masuzawa M, Lee PK, Kamada T, Akeyama T, Abe H, Shimano T, Mori T, Morino H, Ishiguro S: Carcinoembryonic antigen, alpha-fetoprotein and carcinoplacental alkaline phosphatase in gastric carcinoma metastatic to the liver. Cancer 1977;39:1175–1180.
23.
Kodama T, Kameya T, Hirota T, Shimosato Y, Ohkura H, Mukojima T, Kitaoka H: Production of alpha-fetoprotein, normal serum proteins, and human chorionic gonadotropin in stomach cancer: Histologic and immunohistochemical analyses of 35 cases. Cancer 1981;48:1647–1655.
24.
Ishikura H, Fukasawa Y, Ogasawara K, Natori T, Tsukada Y, Aizawa M: An AFP-producing gastric carcinoma with features of hepatoid differentiation: A case report. Cancer 1985;56:840–848.
25.
Ishikura H, Kirimoto K, Shamoto M, Miyamoto Y, Yamagiwa H, Itoh T, Aizawa M: Hepatoid adenocarcinoma of the stomach: An analysis of seven cases. Cancer 1986;58:119–126.
26.
Nagai E, Ueyama T, Yao T, Tsuneyoshi M: Hepatoid adenocarcinoma of the stomach: A clinicopathologic and immunohistochemical analysis. Cancer 1993;72:1827–1835.
27.
Koide N, Nishio A, Igarashi J, Kajikawa S, Adachi W, Amano J: Alpha-fetoprotein-producing gastric cancer: Histochemical analysis of cell proliferation, apoptosis, and angiogenesis. Am J Gastroenterol 1999;94:1658–1663.
28.
Chang YC, Nagasue N, Abe S, Tanimura H, Kumar DD, Nakamura T: Comparison between the clinicopathologic features of AFP-positive and AFP-negative gastric cancers. Am J Gastroenterol 1992;87:321–325.
29.
Ohtani H, Maeda K, Ogawa Y, Kato Y, Sowa M: Serum levels of alpha-fetoprotein in gastric cancer (in Japanese with English abstract). Jpn J Cancer Clin 1996;42:701–706.
30.
Kunieda K, Saji S, Kawaguchi Y, Katoh M, Sugiyama Y, Umemoto T, Miya K, Fukada D, Inada K, Shimokawa K: The clinicopathological characteristics, proliferative activity and formation of basement membrane of gastric cancer with high serum level of alpha-fetoprotein (in Japanese with English abstract). Jpn J Gastroenterol Surg 1997;30:2231–2238.
31.
Adachi Y, Mori M, Maehara Y, Matsumata T, Okudaira Y, Sugimachi K: Surgical results of perforated gastric carcinoma: An analysis of 155 Japanese patients. Am J Gastroenterol 1997;92:516–518.
32.
Maruyama K: The most important prognostic factors for gastric cancer patients: A study using univariate and multivariate analyses. Scand J Gastroenterol 1987;22:63–68.
33.
Nakamura K, Ueyama T, Yao T, Xuan ZX, Ambe K, Adachi Y, Yakeishi Y, Matsukuma A, Enjoji M: Pathology and prognosis of gastric carcinoma: Findings in 10,000 patients who underwent primary gastrectomy. Cancer 1992;70:1030–1037.
34.
Adachi Y, Oshiro T, Mori M, Maehara Y, Sugimachi K: Tumor size as a simple prognostic indicator for gastric carcinoma. Ann Surg Oncol 1997;4:137–140.
35.
Mori M, Ambe K, Adachi Y, Yakeishi Y, Nakamura K, Hachitanda Y, Enjoji M, Sugimachi K: Prognostic value of immunohistochemically identified CEA, SC, AFP, and S-100 protein-positive cells in gastric carcinoma. Cancer 1988;62:534–540.
36.
Ikeda Y, Mori M, Adachi Y, Matsushima T, Sugimachi K, Saku M: Carcinoembryonic antigen (CEA) in stage IV gastric cancer as a risk factor for liver metastasis: A univariate and multivariate analysis. J Surg Oncol 1993;53:235–238.
37.
Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, Kato Y: Incidence of lymph node metastasis from early gastric cancer: Estimation with a large number of cases at two large centers. Gastric Cancer 2000;3:219–225.
38.
Maehara Y, Okuyama T, Oshiro T, Baba H, Anai H, Akazawa K, Sugimachi K: Early carcinoma of the stomach. Surg Gynecol Obstet 1993;177:593–597.
39.
Matsukuma A, Furusawa M, Tomoda H, Seo Y: A clinicopathological study of asymptomatic gastric cancer. Br J Cancer 1996;74:1647–1650.
40.
Adachi Y, Mori M, Maehara Y, Kitano S, Sugimachi K: Prognostic factors of node-negative gastric carcinoma: Univariate and multivariate analyses. J Am Coll Surg 1997;184:373–377.
41.
Adachi Y, Suematsu T, Yasuda K, Shiromizu A, Shiraishi N, Kitano S: Clinicopathologic study of gastric cancer based on Dukes’ classification. World J Surg 1999;23:499–501.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.